Becton, Dickinson and Company (BDX)
Becton Dickinson in talks to divest life sciences unit, FT reports
Medical device maker Becton Dickinson has begun discussions to sell its life sciences division, valued at $21 billion, and is in talks with competitors such as Thermo Fisher Scientific and Danaher , the Financial Times reported on Tuesday.
Becton Dickinson Could Be Cure To Demand For Medtech Supplies, With Robust Pipeline
Becton Dickinson gets rating buy in my first coverage of this stock. Macro demand for medtech and surgical supplies could favor this globally diversified firm with an active portfolio and growth pipeline. The firm is a proven dividend grower and cashflow generator with low debt/equity and investment-grade credit ratings.
BDX Stock Declines Following Class I Classification for Alaris Recall
BD's recall of Alaris infusion pumps following software issues has been classified as the most severe recall by the FDA. A suspension of sales may hurt the top line going forward.
BDX Shares May Climb as GalaFLEX LITE Trial Hits Key Milestone
BD advances its clinical trial for the bioabsorbable GalaFLEX LITE scaffold, aiming to improve outcomes in breast implant revision surgeries and patient recovery.
Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Becton Dickinson (BDX) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Becton Dickinson (BDX) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Becton, Dickinson and Company (BDX) Barclays 27th Annual Global Healthcare Conference Transcript
Becton, Dickinson and Company (NYSE:BDX ) Barclays 27th Annual Global Healthcare Conference March 11, 2025 8:30 AM ET Company Participants Tom Polen - Chairman, Chief Executive Officer and President Chris DelOrefice - Executive Vice President and Chief Financial Officer Conference Call Participants Unidentified Analyst [Call Starts Abruptly] Everyone for joining us today. We are so pleased to have with us again this year the team from Becton, Dickinson, Tom Polen, Chairman, Chief Executive Officer and Chris DelOrefice, EVP and Chief Financial Officer.
Here's Why Becton Dickinson (BDX) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Compared to Estimates, Becton Dickinson (BDX) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Becton Dickinson (BDX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
